Please login to the form below

Not currently logged in
Email:
Password:

Oestrogen-only HRT may raise asthma risk

Postmenopausal women who used oestrogen-only HRT had a significant increase in risk of developing asthma according to a recent study

Results from a recent study show that postmenopausal women who used oestrogen-only hormone replacement therapy (HRT) had a significant increase in risk of developing asthma, compared with women who had never used HRT.

The study, conducted by French researchers and published in the journal Thorax, involved around 57,500 women, none of whom had asthma before the menopause at the start of the trial in 1990. During the course of the next 12 years, 569 women developed asthma.

The research showed that women who took oestrogen-only HRT had a 54 per cent increase in risk of developing asthma compared to non-users. And overall, those who took any form of HRT had a "non-significant" 21 per cent increase of developing the respiratory disorder compared to those who have never taken the therapies.

Director of Asthma UK, Leanne Metcalf, said: "This is the first large-scale and long-term study to suggest that it is oestrogen-only HRT which significantly increases the risk [of asthma]."

However, the authors stressed that the findings should be viewed "in the light of all the other health effects of HRT use," which include quality of life improvements.

9th February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics